These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 12723745)

  • 21. [Safety of specific cyclo-oxygenase 2 inhibitors].
    Lems WF; van de Laar MA; Bijlsma JW
    Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1044-7. PubMed ID: 11414163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
    Hippisley-Cox J; Coupland C; Logan R
    BMJ; 2005 Dec; 331(7528):1310-6. PubMed ID: 16322018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective COX-2 inhibitors and gastrointestinal mucosal injury: pharmacological and therapeutic considerations.
    Dajani EZ; Agrawal NM
    J Assoc Acad Minor Phys; 2000; 11(2-3):28-31. PubMed ID: 10953541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
    Laine L
    Rev Gastroenterol Disord; 2003; 3 Suppl 4():S30-9. PubMed ID: 14671512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptic ulcer disease today.
    Yuan Y; Padol IT; Hunt RH
    Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):80-9. PubMed ID: 16456574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.
    Rahme E; Nedjar H; Bizzi A; Morin S
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1387-98. PubMed ID: 17892525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Proton pump inhibitor H2 receptor antagonist].
    Shiotani A; Kamada T; Kusunoki H; Manabe N; Haruma K
    Nihon Rinsho; 2011 Jun; 69(6):1032-8. PubMed ID: 21688623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
    Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA
    Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapies for ulcers associated with nonsteroidal antiinflammatory drugs.
    Chan FK; Sung JJ
    N Engl J Med; 1998 Jul; 339(5):349-50; author reply 350-1. PubMed ID: 9696650
    [No Abstract]   [Full Text] [Related]  

  • 32. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.
    Lazzaroni M; Bianchi Porro G
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 2():48-58. PubMed ID: 15335413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
    Chen JT; Pucino F; Resman-Targoff BH
    J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF; Oakley SP; Major GA
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prevention and therapy of NSAID-induced ulcers: fact versus myth].
    Fried M; Bertschinger P
    Schweiz Med Wochenschr; 1996 Sep; 126(37):1569-72. PubMed ID: 8927961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The management of upper gastrointestinal problems in patients taking NSAIDs.
    Prichard P
    Aust Fam Physician; 1991 Dec; 20(12):1739-41. PubMed ID: 1687198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
    Fiorucci S; Santucci L; Distrutti E
    Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
    Haag MD; Bos MJ; Hofman A; Koudstaal PJ; Breteler MM; Stricker BH
    Arch Intern Med; 2008 Jun; 168(11):1219-24. PubMed ID: 18541831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.